The following table provides info on the companies discussed in this article, including EV, short interest, current top biopharma-hedge fund holdings, and BPIQ portfolio holding percentages.

We identified 5 stocks that are likely to move big on cancer readouts this Q1 2025. We classified these as either Big Mover or Suspected Big Mover catalysts depending on stock options volatility data. We highlight 5 of these catalysts in the graphics below. 👇   $ARVN Vepdegestrant (ARV-471) / Metastatic Breast Cancer / Phase 3 » Phase 3 VERITAC-2 trial designed to position vepdegestrant as a backbone ER-targeting therapy in BCA. » Ph2 VERITAC had favorable tolerability at bo

(Posted 9:55am CST) $XBI $79.73 | -1.19% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

(Posted 9:55am CST) $XBI $79.73 | -1.19% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

Summary: The American Society of Clinical Oncology (ASCO) Annual 2022 Meeting is taking place from June 3-7, 2022 See our prior post for...

We used our BPIQ pipeline screener (https://www.bpiq.com/pipeline-screener) to identify companies that might be effected by the upcoming...

The 40th Annual J.P. Morgan Health Care Conference is taking place fully online from January 10-13, 2022. "This premier conference is...